A double-blind, placebo-controlled study of the effect of patch delivered therapy on apathy, motor symptoms and mood in subjects with Parkinson disease

The purpose of this study is to see if the study drug works better than placebo (no active drug) in improving motor skills and non-motor symptoms such as mood and apathy that are part of Parkinson disease. The study drug is applied as a patch that must be worn on the skin. Approximately 600 subjects will be enrolled in this study across 120 participating research centers. Up to 10 subjects are anticipated to be enrolled at Rush. Subjects' participation in the study may last up to 29 weeks and will involve about 11 study visits at the Rush.

You may be eligible to participate in this study if you:

• Be male or female and ≥18 years old at the screening visit
• Have idiopathic Parkinson disease, defined by the cardinal sign, bradykinesia, plus the presence of at least one of the following: resting tremor, rigidity or impairment of postural reflexes, and without any other known or suspected cause of Parkinsonism
• Have unsatisfactory control of Parkinson disease motor symptoms under the current treatment, according to the judgment of the study doctor

You will be excluded from this study if you:

• Are a female who is pregnant or breastfeeding
• Have participated in another investigational drug study or a medical device study within the last 28 days prior to the screening visit or are currently participating in another study of an IMP or a medical device
• Have had prior therapy with a dopamine agonist within 28 days prior to the baseline visit.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.